Established · publishing since 1995Rising activity
Lung Cancer Treatments and MutationsHead and Neck Cancer StudiesHeat shock proteins researchHER2/EGFR in Cancer ResearchTGF-β signaling in diseases
Publications
139
Citations
5,297
Est. group size
~2
Recurring co-author estimate
Active years
32
Publishing since 1995
In context
Among 4,953 established Medicine PIs within our index
Citations: 5,297p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 12.8p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~18 · 0% small-team papers (≤3 authors) · across 2 venues
Publication cadence
Publications per year over the last 10 years — averaging 12.8/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- 245 (PB233): Histone methylation changes of H3K9 and H3K36 in PBMCs as pharmacodynamic biomarkers for Zavondemstat (TACH101), a paninhibitor of KDM4 histone lysine demethylase
European Journal of Cancer · 2024
- Supplementary Methods, Table 1 from Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
2023
- Data from Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
2023
- Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
EClinicalMedicine · 2023
- Supplementary Methods, Table 1 from Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
2023
- Data from Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
2023
Publishes in
- Oncotarget×4
- Translational Oncology×2
- Journal of Biological Chemistry×2
- Head & Neck×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
Similar researchers
By research-topic overlap
- Lindsey D. Hughes
Medicine · University of Michigan
- Tamio Okimoto
Medicine · The Ohio State University
- Jaimin K. Rana
Medicine · University of Michigan
- Ai Ni
Medicine · The Ohio State University
- Angel Qin
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile